




[12] Patent

[11] Patent No.: GC 000093	Number of the Decision to Grant the Patent: 5/220
[45] Date of Publishing the Grant of the Patent: 29/06/2005 4/2005	Date of the Decision to Grant the Patent: 15/03/2005
[21] Application No.: GCC/P/1998/32 [22] Filing Date: 15/11/1998 [72] Inventors: 1- Martin Francis Jones, 2- Christopher John Wallis [73] Owner: Glaxo Group Limited, Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex, UB6 0NN, Great Britain [74] Agent: Nassir Ali Kadasa	[51] Int. Cl. ⁷ : C07D 473/00 [56] Cited Documents: - US 5763607 A (HUA MEI et al.) 09 June 1998 - WO 95/21161 A (WELLCOME FOUND; DALUGE SUSAN MARY; MARTIN MICHAEL TOLAR) 10 August 1995 - WO 91/15490 A (GLAXO INC.; VINCE ROBERT; PETERSON MARK LEE; LACKEY JOHN) 17 October 1991 - EP 0434450 A (WELLCOME FOUND) 26 June 1991 - GB 2217320 A (UNIV MINNESOTA) 25 October 1989 - US 5329008 A (PARTRIDGE JOHN J. et al.) 12 July 1994

[54] PROCESS FOR THE SYNTHESIS OF PHARMACEUTICALLY ACCEPTABLE CHLOROPURINE INTERMEDIATES

[57] Abstract: The present invention relates to a process for the preparation of a carbocyclic purine nucleoside analogue of formula (I), its salts and pharmaceutically acceptable derivatives thereof.



No. of claims: 13